MaxCyte’s non-viral delivery platform allows for engineering of nearly all cell types, including human primary cells, with any molecule, at any scale for use in drug discovery and development, biomanufacturing, gene editing, cell therapy, and immuno-oncology. Its consistency and minimal cell disturbance facilitate rapid, clinical and commercial grade cell engineering.
MicroBiopharm Japan has been manufacturing highly potent compounds by its unique fermentation technology for a long time. These highly potent compounds and their derivatives are used as anticancer drugs usually. In addition, these highly potent compounds could also be used as payloads in the field of ADC such as DM-1 (Ansamitocin P3 derivative), Doxorubicin, Alpha-amanitin, Camptotecin analogues, and so on. MBJ supports customer’s development of ADC drugs by supply these payloads and their linker conjugates with flexibility in compliance to required specification.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery.
Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation… Read More
Morphotek® is a biotechnology company focused on the development of antibody-based therapies. In oncology, we are developing biological therapies that target underlying disease pathways and can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. As part of this approach, we have developed proprietary ADC technologies that utilize REsidue-SPEcific Conjugation Technology™ (RESPECT™) and proprietary payloads to develop ADCs to internal and clients’ strategic targets through our end-to-end ADC Services
NOF Corporation is the leading commercial supplier of activated PEG products and is providing site-specific linkers, such as, linear and branched hetero-activated PEG, and single molecular weight PEGs for the development of next generation Antibody-Drug Conjugates. NOF also supplies ultra-pure polysorbates 20 and 80 for stabilizing the formulation of antibody and protein… Read More.
Pierre FABRE CDMO proposes its international partners a full service, from clinical development to commercial production in the following fields of expertises: manufacturing of APIs, supercritical CO2 formulation, production of pharmaceutical lozenges and fill & finish of injectable products (vials, prefilled syringes), including conventional cytotoxic and biotechnology products… Read More.
Formed in 2016, PROVEO™ is a four-company CMO alliance providing seamless, end-to-end solutions for the process development and cGMP manufacture of ADCs. Combining integrated project management, logistics, supply chain, and production—the PROVEO Alliance blends decades of industry experience and competencies with proven capabilities and the very latest in technological innovation to deliver an unmatched quality, dependability, and… Read More.
Recipharm is a leading CDMO with 3,500 employees, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm operates facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Sweden. Recipharm has extensive experience in medicinal chemistry including specialities such as ADC offerings, radiolabelling and non-GMP scale up chemistry.
Quanta BioDesign was founded for the purpose of developing a line of products involved in drug discovery and diagnostic development. For 30 years the PEGylation of biologics has been completely defined by the use of generally high MW and highly polydispersed PEGs. While showing promising results in the clinic, it has serious limitations in control and characterization. Our single molecular weight ethylene glycol conjugation technology, dPEG, can eliminate common problems found in the development of diagnostic and therapeutic products.